Celsion Corporation Release: Tumor Targeting Docetaxel Abstract Presented at the 11th Liposome Research Days Conference

COLUMBIA, Md.--(BUSINESS WIRE)--CELSION CORPORATION (NASDAQ: CLSN) announced that its docetaxel thermosensitive liposome preclinical study results were presented at the 11th Liposome Research Days Conference during the poster session on July 22, 2008.
MORE ON THIS TOPIC